Press

Release

NEW YORK, Aug 08, 2006 (BUSINESS WIRE) -- ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) announced today the airing of an ABC news report featuring ZIO-201. A replay can be found on the Company's web site at www.ziopharm.com.

This report was aired on ABC's Channel 13 in Houston, Texas on August 2, 2006, and the views and opinions contained therein do not necessarily represent those of the Company. Although the report was neither written nor produced by the Company, the Company believes that the information contained in the report was materially accurate regarding the Company's investigational agent, ZIO-201, as of the date thereof. The Company assumes no obligation to update this information, except as required by law.

About ZIO-201

ZIO-201, the Company's proprietary alkylating drug, is the active metabolite of ifosfamide and, unlike ifosfamide, does not produce the other metabolites causing substantial toxicities. Data in human cancer cell lines, human-mouse xenografts and cancers resistant to cyclophosphamide and ifosfamide indicated ZIO-201 was active at doses similar to those achieved in the phase I trial. The Company recently initiated a phase I/II trial of ZIO-201 in advanced sarcoma. Trials in lymphoma and children's cancers are in late-stage planning, and an oral formulation is being explored.

About ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment. For more information, visit www.ziopharm.com.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, and risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates. The Company assumes no obligation to update these forward-looking statements, except as required by law.

ZIOP-G

SOURCE: ZIOPHARM Oncology

ZIOPHARM Oncology
Investors
Suzanne McKenna, 646-214-0703
    or
Media
Tina Posterli, 917-322-2565
tposterli@rxir.com

Copyright Business Wire 2006

News Provided by COMTEX